Fezolinetant Market

The Fezolinetant market is witnessing a CAGR of 4.5% during the forecast period of 2025-2035. Fezolinetant, sold under the brand name VEOZAH, is a major leap in the management of moderate to severe vasomotor symptoms (VMS) of menopause. Astellas Pharma Inc. developed this non-hormonal treatment as a selective neurokinin 3 (NK3) receptor antagonist that treats hot flashes and night sweats by influencing the mechanisms of the body’s temperature regulation.

The U.S. Food and Drug Administration (FDA) approval of VEOZAH in May 2023 was a milestone in women’s health, providing a new, non-hormonal therapy for menopausal VMS. The approval was grounded in strong clinical evidence illustrating the safety and efficacy of fezolinetant. Health Canada subsequently approved VEOZAH in December 2024, increasing its availability to North American women with menopausal symptoms.

The launch of fezolinetant to the pharmaceutical sector fills an existing unmet requirement for non-hormonal remedies for menopausal VMS. The conventional hormone replacement therapies (HRT) have worked but are inappropriate for all women, most especially those with contraindications toward the use of estrogen. Fezolinetant presents a solution in that it specifically targets the NK3 receptor and is able to mitigate the frequency and severity of hot flashes without the administration of hormones.

Astellas Pharma’s emphasis on women’s health as a strategic priority has made fezolinetant a central element of their portfolio. The firm’s investment in large-scale clinical trials, such as the SKYLIGHT series, has yielded robust data in favor of the drug’s efficacy and safety profile. These trials have been crucial in obtaining regulatory approvals and in establishing confidence among healthcare professionals and patients. Fezolinetant, sold under the brand name VEOZAH, is a major leap in the management of moderate to severe vasomotor symptoms (VMS) of menopause. Astellas Pharma Inc. developed this non-hormonal treatment as a selective neurokinin 3 (NK3) receptor antagonist that treats hot flashes and night sweats by influencing the mechanisms of the body’s temperature regulation.

The U.S. Food and Drug Administration (FDA) approval of VEOZAH in May 2023 was a milestone in women’s health, providing a new, non-hormonal therapy for menopausal VMS. The approval was grounded in strong clinical evidence illustrating the safety and efficacy of fezolinetant. Health Canada subsequently approved VEOZAH in December 2024, increasing its availability to North American women with menopausal symptoms.